The Use of Genomics to Drive Kidney Disease Drug Discovery and Development | Zendy

Dermot F. Reilly | Zendy; Matthew D. Breyer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Use of Genomics to Drive Kidney Disease Drug Discovery and Development

Author(s) -

Dermot F. Reilly,

Matthew D. Breyer

Publication year - 2020

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.11070919

Subject(s) - medicine , drug development , disease , kidney disease , genomics , bioinformatics , drug , drug discovery , pharmacogenetics , genetic testing , population , precision medicine , computational biology , intensive care medicine , gene , pharmacology , genetics , genome , pathology , biology , genotype , environmental health

As opposed to diseases such as cancer, autoimmune disease, and diabetes, identifying drugs to treat CKD has proven significantly more challenging. Over the past 2 decades, new potential therapeutic targets have been identified as genetically altered proteins involved in rare monogenetic kidney diseases. Other possible target genes have been implicated through common genetic polymorphisms associated with CKD in the general population. Significant challenges remain before translating these genetic insights into clinical therapies for CKD. This paper will discuss how genetic variants may be leveraged to develop drugs and will especially focus on those genes associated with CKD to exemplify the value and challenges in including genetic information in the drug development pipeline.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research